Table 3.

Demographic, clinical data of the cohort

Number of patients		Overall cohort	Ongoing BTZ treatment (OT)	BTZ treatment in the past (PT)
		70	34	36
Sex	Male/female	50/20	24/10	26/10
Age in years	Median	66	64	66
	(Range)	(31–82)	(47–81)	(31–82)
Neuropathy		63	30	33
Painful neuropathy		33	12	21
Severity grades
Grade 1		22	12	10
Grade 1 with pain		14	6	8
Grade 2		7	5	2
Grade 2 with pain		17	6	11
Grade 3 (with pain)		3 (2)	1	2 (2)
Abnormal findings
Sensory function		61	29	32
Motor function		25	9	16
QSTa		52	24	28
Electrophysiology
Probably axonal		14	9	5
Axonal		33	11	22
Demyelinating		2	0	2
Myeloma classification
Heavy chain IgA		12	6	6
Heavy chain IgG		39	19	20
Heavy chain IgM		1	1	0
Light chain kappa LC		40	21	19
Light chain lambda LC		26	14	12
ODSSb	Median	2	1.5	2
	(Range)	(0–7)	(0–7)	(0–6)
MRCc sum score	Median	120	120	120
	(Range)	(99–120)	(102–120)	(99–120)
mTCNSd sum score	Median	11	10.5	13
	(Range)	(0–29)	(0–23)	(0–29)
NPSIe sum score	Median	10	8	18
	(Range)	(0–91)	(0–51)	(0–91)
Disease duration in months	Median	44.0	34.5	44
	(Range)	(2–205)	(2–163)	(4–205)
Cumulative dose (mg/m2)	Median	22.8	33.4	20.8
	(Range)	(3.9–227.2)	(8.6–153.4)	(3.9–227.2)
Time since last application in months	Median	2	0	16.5
	(Range)	(0–115)	(0–6)	(1–115)

Italic values displays the range

^aQST Quantitative sensory testing

^bODSS Overall disability sum score

^cMRC Medical research council

^dmTCNS Modified toronto clinical neuropathy score

^eNPSI Neuropathic pain symptom inventory